ライフサイエンスコーパス: maculopathy

1 istent uveitis, persistent hyphema, hypotony maculopathy).

2 users or severe retinal toxicity (bull's eye maculopathy).

3 tion of the pathologic findings of optic pit maculopathy.

4 e users, including those at highest risk for maculopathy.

5 sease and describe 3 stages of a CRF-related maculopathy.

6 bleb revision to correct persistent hypotony maculopathy.

7 of eye care visits and diagnostic tests for maculopathy.

8 ar diseases, except those caused by diabetic maculopathy.

9 sence of coexisting paracentral acute middle maculopathy.

10 roviders and diagnostic testing to check for maculopathy.

11 We describe 3 stages of a unique CRF-related maculopathy.

12 R, majority had NPDR (93.4%), while 5.3% had maculopathy.

13 dence of concurrent paracentral acute middle maculopathy.

14 g420Ser mutation presented with a bull's eye maculopathy.

15 accessible, and sensitive to the severity of maculopathy.

16 underwent grid photocoagulation for diabetic maculopathy.

17 No eye had associated maculopathy.

18 as glaucoma, retinal detachment, and myopic maculopathy.

19 ification and Grading System for Age-Related Maculopathy.

20 suppress radiation optic neuropathy (RON) or maculopathy.

21 ions in RDH5 and suffered from FAP with mild maculopathy.

22 culopathies such as paracentral acute middle maculopathy.

23 field in early stages of hydroxychloroquine maculopathy.

24 ermany) in persons with and without diabetic maculopathy.

25 rix and previously implicated in early-onset maculopathy.

26 control subjects and patients with diabetic maculopathy.

27 ared with those in aged control eyes without maculopathy.

28 despread retinal degeneration with prominent maculopathy.

29 the management of radiation retinopathy and maculopathy.

30 oven treatments for radiation retinopathy or maculopathy.

31 expansion is an early change in age-related maculopathy.

32 , and even heterozygous carriers can exhibit maculopathy.

33 tional Classification System for Age-Related Maculopathy.

34 dystrophy and one with bilateral progressive maculopathy.

35 macular fluid resolution, and recurrence of maculopathy.

36 method (R(2) = 0.22, P = 0.024) in eyes with maculopathy.

37 sociated with an unusual AMD-like late-onset maculopathy.

38 dependent birth cohort effect on age-related maculopathy.

39 CI: 0.83, 128.58) for exudative age-related maculopathy.

40 function observed in ageing and age-related maculopathy.

41 ar deposit, which accumulates in age-related maculopathy.

42 ents alone and in combination on age-related maculopathy.

43 ent use affects the incidence of age-related maculopathy.

44 een smoking and the incidence of age-related maculopathy.

45 me lesions associated with early age-related maculopathy.

46 r fluid and long-term avoidance of recurrent maculopathy.

47 patients with AMD and unilateral neovascular maculopathy.

48 l atrophy, which resembles pathologic myopic maculopathy.

49 should be performed to rule out preexisting maculopathy.

50 ndus photographs for retinal hemorrhages and maculopathy.

51 xhibit features resembling pathologic myopic maculopathy.

52 ith or without maculopathy or mild NPDR with maculopathy.

53 G), all conferring a reduced risk for toxic maculopathy.

54 AMD-associated variants on the risk of toxic maculopathy.

55 stitution with evidence of tamoxifen-induced maculopathy.

56 r evidence for any other cause of bull's eye maculopathy.

57 enetic association studies of rare inherited maculopathies.

58 intraretinal fluid across various exudative maculopathies.

59 ded to regions of SSPiM in several exudative maculopathies.

60 important implications in the management of maculopathies.

61 There were 183 individuals without any maculopathy, 200 with mild maculopathy, 325 with interme

62 een of the 64 eyes with low IOP had hypotony maculopathy (23.4%).

63 Among those at high risk for maculopathy, 27.9% lacked regular eye care visits, 6.1%

64 duals without any maculopathy, 200 with mild maculopathy, 325 with intermediate disease, and 222 with

65 therapy-related complications were radiation maculopathy (43.1%) and radiation optic neuropathy (20.8

66 (75%); proliferative retinopathy, 24% (32%); maculopathy, 56% (65%); papillopathy, 61% (77%); catarac

67 hytherapy-related complication was radiation maculopathy (66% of patients), followed by radiation opt

68 cidence of bleb revision in patients who had maculopathy (7.6 vs. 1.9 revisions/100 person-years; for

69 s, 35% of CD and 51% of CRD had a bull's eye maculopathy; 70% of CRD showed absolute peripheral visua

70 en patients (76.5%) had a clinical radiation maculopathy; 8 patients (47.1%) had macular cysts on OCT

71 nal case series of 4 patients with optic pit maculopathy, a complete ophthalmic evaluation, with fund

72 ith acute exudative polymorphous vitelliform maculopathy (AEPVM).

73 damental insights into the unique biology of maculopathies affecting the RPE-ECM interface.

74 ctive and simple technique to treat hypotony maculopathy after glaucoma surgery.

75 of IOP and improved VA in eyes with hypotony maculopathy after previous glaucoma filtering surgery.

76 een January 2011 and July 2014 for radiation maculopathy after proton beam therapy were included.

77 atus (ELOVL2, FADS1, and FADS2), and various maculopathies (ALDH3A2 and RPE65).

78 tive paraneoplastic polymorphous vitelliform maculopathy, although with less distinct appearance and

79 e patient-specific hiPSCs to model and study maculopathies, an important class of blinding disorders

80 relation of cigarette smoking to age-related maculopathy, an important cause of blindness in the Unit

81 o be significantly enriched in patients with maculopathies and cone disorders (6/488) compared with e

82 ong positive association between age-related maculopathy and age, when comparing participants from th

83 e involved in the development of age-related maculopathy and age-related macular degeneration.

84 Age-related maculopathy and atherosclerotic cardiovascular disease m

85 l thickness is an important factor in myopic maculopathy and can be a better indicator of its severit

86 full-thickness LC defects unassociated with maculopathy and different from glaucomatous acquired pit

87 t report on the prognosis of acute traumatic maculopathy and extramacular commotio retinae.

88 wo-generation family with autosomal dominant maculopathy and identified a rare variant p.Glu1144Lys i

89 e to unmeasured risk factors for age-related maculopathy and limitations of risk factor measurements.

90 International Classification of Age-related Maculopathy and Macular Degeneration.

91 toxicity eventually leading to irreversible maculopathy and retinopathy.

92 tional Classification System for age-related maculopathy and stratified using the Rotterdam staging s

93 also referred to as paracentral acute middle maculopathy, and 5 eyes (4 patients) had type 2 SD-OCT l

94 worse, color vision disturbances, bull's eye maculopathy, and peripheral pigmentary retinopathy.

95 nt for additional glaucoma surgery, hypotony maculopathy, and serious complications were also conside

96 and cumulative incidence of any retinopathy, maculopathy, and sight-threatening diabetic retinopathy

97 primary goal of therapy for paraproteinemic maculopathy, and this can be achieved by a systemic rout

98 ure; short stature; hearing loss; pigmentary maculopathy; and renal tubular dysfunction.

99 traction mechanisms causing myopic traction maculopathy are diverse.

100 amily determinants of lesions of age-related maculopathy are likely, less so for age-related cataract

101 Radiation retinopathy and maculopathy are predictable complications resulting from

102 large reductions in the risk of age-related maculopathy are unlikely.

103 aphic evidence of early and late age-related maculopathy (ARM) among persons over age 40 years (n = 8

104 ng in ARMA, a study of aging and age-related maculopathy (ARM) ancillary to the Health, Aging, and Bo

105 lassified into two groups: early age-related maculopathy (ARM) and neovascular AMD.

106 (MMP2) genes are associated with age-related maculopathy (ARM) in older women.

107 n and the long-term incidence of age-related maculopathy (ARM) in people in the Beaver Dam Eye Study

108 Age-related maculopathy (ARM) is a leading cause of visual impairmen

109 Age-related maculopathy (ARM) is a leading cause of visual impairmen

110 -related macular degeneration or age-related maculopathy (ARM) is a major public health issue, as it

111 Age-related maculopathy (ARM) is an important cause of visual impair

112 Age-related maculopathy (ARM) is one of the most common causes of bl

113 The pathogenesis of age-related maculopathy (ARM) is related to adverse vascular changes

114 d the 5-year incidence of early, age-related maculopathy (ARM) were investigated in a population-base

115 Macular drusen are hallmarks of age-related maculopathy (ARM), but these focal extracellular lesions

116 Age-related maculopathy (ARM), or age-related macular degeneration,

117 tary factors have been linked to age-related maculopathy (ARM), the early form of age-related macular

118 tudies of families affected with age-related maculopathy (ARM), we previously identified a significan

119 in aging and lesion formation in age-related maculopathy (ARM).

120 s test and the focal cone ERG in age-related maculopathy (ARM).

121 esions associated with aging and age-related maculopathy (ARM).

122 ior uveitis with acute hypotony and hypotony maculopathy as their first uveitic episode.

123 y, chronic central serous chorioretinopathy, maculopathy associated with hydroxychloroquine, and heal

124 d population, many patients at high risk for maculopathy associated with the use of chloroquine or hy

125 out generalized photoreceptor dysfunction to maculopathy associated with very severe rod-cone dysfunc

126 who did not have a diagnosis of age-related maculopathy at baseline (1982).

127 Since 2006, 53 patients with hypotony maculopathy attributable to overfiltration following gla

128 ) were performed in patients with bull's-eye maculopathy (BEM) to identify phenotypic markers that ca

129 per-reflective spot resembling that in ghost maculopathy, but corresponding SD OCT images were consis

130 nt vitreoretinal surgery for myopic traction maculopathy by a single surgeon at a tertiary referral c

131 ain changes in the prevalence of age-related maculopathy by age.

132 The peculiar features of cavitary optic disc maculopathy can be explained only by considering the pre

133 BCVA reduction in eyes with dry-type myopic maculopathy can be related to a thinner macular choroida

134 Paraproteinemic maculopathy can be unilateral.

135 Acute exudative polymorphous vitelliform maculopathy can present with a more variable natural cou

136 pathy, traumatic choroidal rupture, diabetic maculopathy, central serous retinopathy, and macular dru

137 Among individuals with no or minimal maculopathy, CFH variants were associated with more than

138 cavitation, are associated with an enigmatic maculopathy characterized by schisis-like thickening and

139 hearing loss was referred for an unspecified maculopathy detected during screening evaluation for dia

140 Accelerated AMD-like maculopathy develops in patients with retinal iron overl

141 Cavitary optic disc maculopathy develops when fluctuating pressure gradients

142 by altered choroidal hemodynamics, including maculopathies, diabetic retinopathy, and glaucoma.

143 ers, and 34.5% had no diagnostic testing for maculopathy during the 5-year period.

144 s had progressive visual loss from a type of maculopathy during the last 40 years of his life.

145 The types of maculopathies encountered were: a full-thickness macular

146 sociated with retinoschisis, myopic traction maculopathy, epiretinal membrane, vitreoretinal traction

147 D can occur in cases of high myopic traction maculopathy, especially in those without obvious vitreom

148 f 22 consecutive patients with cavitary disc maculopathy evaluated by a single surgeon between 1991 a

149 3/60) due to macular diseases, with diabetic maculopathy excluded.

150 d markedly reduced visual acuity, bull's eye maculopathy, foveal hyperpigmentation, peripapillary atr

151 ed by using a modified Wisconsin Age-Related Maculopathy Grading Scale (a 6-level scale: 10, no AMD;

152 AMD lesions using the Wisconsin Age-Related Maculopathy grading scheme.

153 graded according to the Clinical Age-Related Maculopathy Grading System (CARMS) as grade 1 (no AMD),

154 were graded using the Wisconsin Age-related Maculopathy Grading System (n = 5).

155 were graded using the Wisconsin Age-Related Maculopathy Grading System (WARMGS).

156 raphs according to the Wisconsin Age-Related Maculopathy Grading System and Airlie House classificati

157 assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photographs and ad

158 The Wisconsin Age-Related Maculopathy Grading System was used to grade features of

159 g classifications (the Wisconsin age-related maculopathy grading system, the international classifica

160 aded for AMD using the Wisconsin Age-related Maculopathy Grading System.

161 phy using the modified Wisconsin Age-Related Maculopathy Grading System.

162 raphs according to the Wisconsin Age-Related Maculopathy Grading System.

163 raphs according to the Wisconsin Age-Related Maculopathy Grading System.

164 raded using a modified Wisconsin Age-Related Maculopathy Grading System.

165 a modification of the Wisconsin Age-Related Maculopathy Grading System.

166 raphs according to the Wisconsin Age-Related Maculopathy grading system.

167 was determined by the Wisconsin Age-Related Maculopathy Grading System.

168 photographs using the Wisconsin Age-related Maculopathy Grading System.

169 photographs using the Wisconsin Age-Related Maculopathy Grading System.

170 phy using the modified Wisconsin Age-Related Maculopathy Grading System.

171 nt mottling in 27 patients (63%) and lacunar maculopathy in 3 (6.9%).

172 inopathy or worse, or clinically significant maculopathy in either or both eyes.

173 lated macular degeneration (AMD), a frequent maculopathy in individuals over 55 years of age, and (2)

174 o determine whether age-related cataract and maculopathy in older siblings predicts development of th

175 We ascertained the clinical course of maculopathy in paraproteinemia and investigated the effe

176 al vasculopathy and paracentral acute middle maculopathy include eye compression injury causing globa

177 Eyes with various forms of exudative maculopathy including diabetic retinopathy (DR), retinal

178 ce may be used to classify paracentral acute maculopathy into distinct subtypes.

179 Optic disc pit with associated maculopathy is a known entity.

180 Recessive Stargardt maculopathy is another central blinding disease caused b

181 Tamoxifen maculopathy is characterized by cavitation in the centra

182 people in the United States with age-related maculopathy is increasing in recent years because of inc

183 ent of genetic factors contributing to toxic maculopathy is largely unclear.

184 Myopia-related maculopathy is one of the leading causes of blindness in

185 Ghost maculopathy is the phenomenon of an imaging artifact app

186 orrhage [k; 95 % CI = 0.60 (0.41-0.78)], and maculopathy [k; 95 % CI = 0.52 (0.43-0.60)].

187 = 0.68 (0.52-0.84)], moderate agreement for maculopathy [k; 95 % CI = 0.59 (0.50-0.67)].

188 from 5 centers with paracentral acute middle maculopathy lesions and previously unreported retinal va

189 Paracentral acute middle maculopathy lesions correspond to preservation of perfus

190 T analysis of these paracentral acute middle maculopathy lesions demonstrated subsequent thinning of

191 Paracentral acute middle maculopathy lesions may develop in a wide spectrum of re

192 alysis excluded most of the previously known maculopathy loci.

193 Paracentral acute middle maculopathy may be best evaluated with the use of en fac

194 Bilateral, profound hypotony maculopathy may present acutely in idiopathic acute ante

195 Paracentral acute middle maculopathy may represent a novel variant of AMN that af

196 macular edema, clinically evident radiation maculopathy, moderate vision loss, and poor visual acuit

197 Ten eyes had stage 3 CRF-related maculopathy, more common in older individuals with more

198 cal pathogenic mechanism responsible for the maculopathy, namely, dynamic fluctuations in the gradien

199 ere more likely to develop early age-related maculopathy (odds ratio (OR) per 10 pack-years smoked =

200 Forty-seven eyes (20 normal, 27 with maculopathy) of 47 patients (mean age, 59.0 +/- 19.0 yea

201 Eight patients (67%) had obvious maculopathy on fundus examination.

202 , subretinal neovascularization, age-related maculopathy, optic nerve disorders, and nerve fiber laye

203 ve complications include characterization of maculopathy or corneal wound integrity, assessment of IO

204 or worse in 3 eyes, of which all had myopic maculopathy or deep amblyopia.

205 , or proliferative DR (PDR), with or without maculopathy or mild NPDR with maculopathy.

206 STDR; defined as proliferative DR, referable maculopathy, or both) was 21.0% (95% CI, 16.7%-25.3%).

207 dence (0%) of radiation-induced retinopathy, maculopathy, or optic neuropathy.

208 e age-related macular degeneration, diabetic maculopathy, or retinal vein occlusion.

209 /100 person-years; for maculopathy versus no maculopathy P = 0.008).

210 (P = 0.045) and clinically evident radiation maculopathy (P = 0.040) in the bevacizumab group compare

211 13), and 0.050 (-0.40, 0.70) in Junius Kuhnt maculopathy (p = 0.344).

212 lusion illustrating paracentral acute middle maculopathy (PAMM) in a perivenular fern-like pattern wi

213 (SD-OCT) finding of paracentral acute middle maculopathy (PAMM) that can be associated with acute mac

214 tion complications, which included radiation maculopathy, papillopathy, retinal detachment, and rubeo

215 Sequencing of 192 maculopathy patients revealed additional rare variants,

216 Persistent placoid maculopathy (PPM) is a rare clinical entity with feature

217 inopathy (human graded as either ungradable, maculopathy, preproliferative, or proliferative), 99.6%

218 Surgical repair for hypotony maculopathy provided a significant improvement in VA at

219 All 6 eyes demonstrated a pigmentary maculopathy ranging from mild to pronounced.

220 mm(-1) in eyes with paracentral acute middle maculopathy (reduction -19.4%, P = .04).

221 mm(-1) in eyes with paracentral acute middle maculopathy (reduction -6.0%, P = .08).

222 Paracentral acute middle maculopathy refers to characteristic hyper-reflective sp

223 nsignificant 13% reduced risk of age-related maculopathy (relative risk = 0.87, 95 percent confidence

224 Permanent cure of the maculopathy requires either elimination of the translami

225 The maculopathy resolved partially or completely in 17 patie

226 Patients with age-related maculopathy sensitivity 2 (ARMS2) risk alleles derived m

227 Maculopathy showed residual foveal islands or extensive

228 gories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system.

229 f AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fundus photogr

230 s made according to the Clinical Age-Related Maculopathy Staging System.

231 opathy Study (2001-2002) and the Age-Related Maculopathy Statin Study (2004-2006).

232 Age-related maculopathy status was determined by grading stereoscopi

233 s: the Cardiovascular Health and Age-Related Maculopathy Study (2001-2002) and the Age-Related Maculo

234 (346 sib pairs) from the Family Age Related Maculopathy Study (FARMS).

235 evious GWS on AMD (FARMS [Family Age-Related Maculopathy Study]sample of 34 extended families) lookin

236 idiopathic condition resembling other acute maculopathies such as paracentral acute middle maculopat

237 sterile vitreitis, endophthalmitis, hypotony maculopathy, suprachoroidal hemorrhage, retinal detachme

238 r 2 alleles associated with AMD, age-related maculopathy susceptibility 2 (ARMS2) and complement fact

239 body mass index, smoking status, age-related maculopathy susceptibility 2 (ARMS2) and complement fact

240 s of the A69S risk allele in the age-related maculopathy susceptibility 2 (ARMS2) gene (P < .001).

241 the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes, genotyped or

242 he complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.

243 ent Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS3793917 were inde

244 ent factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490924 polymorp

245 complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), complement co

246 amino acid substitutions in the age-related maculopathy susceptibility 2 gene linked to AMD, Ala(69)

247 es in a joint effect analysis of Age-Related Maculopathy Susceptibility 2 rs10490924 and Complement F

248 established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)-HTRA1 (HtrA serine peptida

249 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-temperature requiremen

250 enes [complement factor H (CFH), age-related maculopathy susceptibility 2/high-temperature requiremen

251 ement factor H (CFH) and A69S in age-related maculopathy susceptibility locus 2 (ARMS2).

252 andheld laser devices can cause a variety of maculopathies that can reduce central vision permanently

253 quine users and those at high risk for toxic maculopathy, the proportions with regular eye care visit

254 e "ghost image" in this phenomenon of "ghost maculopathy." The ghost image was present consistently o

255 In patients with diabetic maculopathy there was no significant difference between

256 antly reduce susceptibility to develop toxic maculopathy under CQ treatment.

257 ducted two genome-wide scans for age-related maculopathy using the Center for Inherited Disease Resea

258 that now can be expanded to include torpedo maculopathy, vascular changes, and hemorrhagic retinopat

259 (7.6 vs. 1.9 revisions/100 person-years; for maculopathy versus no maculopathy P = 0.008).

260 ntravitreal ranibizumab therapy for diabetic maculopathy was 0.9981 QALY, equating to an 11.6% improv

261 ively; that for clinically evident radiation maculopathy was 16% versus 31% (P = 0.001), respectively

262 Mean duration of hypotony maculopathy was 4.98 +/- 8.93 months.

263 Hypotony maculopathy was characterized by the presence of a decre

264 Diabetic maculopathy was found in 14.5% (59/407) of all participa

265 notypes including exudative and nonexudative maculopathy was observed, with onset in the late fifth d

266 Maculopathy was unilateral in 9 cases and occurred at a

267 ch for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Li

268 geographic atrophy, or evidence of exudative maculopathy were coded as affected for the purpose of th

269 Lesions typical of age-related maculopathy were determined by masked grading of stereos

270 Lesions associated with early age-related maculopathy were distributed in specific patterns.

271 of 16 patients with paracentral acute middle maculopathy were evaluated.

272 62 patients with various forms of exudative maculopathy were evaluated; 60 eyes with DR, 9 eyes with

273 All eyes with ghost maculopathy were found to be pseudophakic with a posteri

274 Those at high risk for maculopathy were identified.

275 us lesions associated with early age-related maculopathy were located in specific patterns in the mac

276 ry abnormalities associated with age-related maculopathy were more prevalent in the superior or nasal

277 ted volunteers and 21 patients with diabetic maculopathy were recruited.

278 rom 8 patients with paracentral acute middle maculopathy were reviewed and analyzed.

279 retinal pathologies, retinal hemorrhage, and maculopathy were substantial both for the ophthalmologis

280 otherwise known as paracentral acute middle maculopathy, were observed in all patients at baseline p

281 ent age groups, except for early age-related maculopathy, where older age increased the association.

282 Medical records of 33 patients with hypotony maculopathy who underwent primary bleb revision between

283 sed study, 20 eyes of 10 patients presenting maculopathies with various degrees of impairment of the

284 has the potential to provide patients having maculopathy with a new tool to monitor their vision at h

285 The mildest disease was a subtle maculopathy with relatively limited peripheral retinal d

286 gment epithelium and cystoid or schisis-like maculopathy with typical functional findings remain clas

287 a total of 279 incident cases of age-related maculopathy with vision loss to 20/30 or worse were conf

288 develop when visual function is adapting to maculopathy, with the use of each depending on the brigh

289 rfamilial variability, ranging from isolated maculopathy without generalized photoreceptor dysfunctio

290 detachment in patients with myopic traction maculopathy without posterior vitreous detachment.